When it comes to global pharma pricing and market access, this moment is one of unprecedented change. As policy initiatives like Most Favoured Nations (MFN) and the EU’s Joint Clinical Assessment ...

Women with polyendocrine metabolic ovarian syndrome (PMOS) in the UK should get diagnosed sooner and be offered an annual review of their condition, according to new guidance from NICE. Draft guidance ...

In its second acquisition of the week, Ipsen will take control of Memo Therapeutics and a first-in-class drug for BK ...

Tregzi is the second cell therapy to be approved by the FDA for use in the context of managing GVHD in HSCT patients, albeit ...

As the US relaxes an export ban on Anthropic's advanced AI tools, the company formally launched Claude Science, an AI ...

Vistagen has chalked up another trial failure for fasedienol, its drug candidate for social anxiety disorder (SAD), cratering ...

Patients with newly diagnosed mantle cell lymphoma (MCL) could avoid chemotherapy with a regimen based on BeOne Medicines' ...

Sanofi is preparing to expand the use of its Pompe therapy Nexviazyme, currently approved only for late-onset cases of the ...

Eli Lilly, Regeneron, and five other companies have been selected to take part in the FDA's PreCheck pilot programme, designed to make it easier and quicker to set up US manufacturing facilities. The ...

Members of the China Select Committee in the US House have launched a national security investigation into a number of big pharma companies, asking for details of their use of clinical trial sites in ...

Unicycive Therapeutics' hopes of getting FDA approval of its drug for hyperphosphataemia in patients with chronic kidney disease (CKD) who need dialysis have been knocked back again. The US regulator ...

Earlier this year, Daiichi Sankyo Global Head of Oncology Ken Keller told pharmaphorum about the company’s big year, with ...